Abstract:Background Neonatal sepsis is one of the major causes of morbidity and mortality in newborns. However, atypical clinical manifestations and symptoms make the early diagnosis of neonatal sepsis a challenge. Relatively high-serum soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated as a diagnostic biomarker for adult sepsis. Therefore, the meta-analysis is intended to explore the diagnostic value of suPAR for neonatal sepsis. Methods The PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, China Biological Medicine Disk, and Wanfang databases were retrieved from inception to 31 December 2022 to collect diagnostic accuracy studies about suPAR for neonatal sepsis. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias in the included studies using the quality assessment of diagnostic accuracy studies-2 (QUADAS-2) tool. Then, a meta-analysis was performed using Stata 15.0 software. Results A total of six articles involving eight studies were included. The results of the meta-analysis showed that the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.89 [95%CI (0.83–0.93)], 0.94 [95%CI (0.77–0.98)], 14 [95%CI (3.5–55.2)], 0.12 [95%CI (0.08–0.18)], and 117 [95%CI (24–567)], respectively. The area under the curve (AUC) of summary receiver operator characteristic (SROC) curves was 0.92 [95%CI (0.90–0.94)]. Sensitivity analysis confirmed the stability of the results, and publication bias was not observed. Fagan’s nomogram results demonstrated the clinical availability of the findings. Conclusion Current evidence suggests that suPAR has potential diagnostic value for neonatal sepsis. Owing to the limited quality of the included studies, more high-quality studies are needed to verify the above conclusion.

An ELISA Method Detecting the Active Form of Supar

Urine PLA2R Antibody Detection in Hazard Stratification of PLA2R-Associated Membranous Nephropathy.

Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals

Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels

A Novel ELISA for the Detection of Active Form of Plasminogen Activator Inhibitor-1 Based on a Highly Specific Trapping Agent.

Immunoradiometric Assay of Human Soluble Urokinase Receptor and Its Clinical Application

Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method

Expression and Activity Detection of the Humanized Anti-Upar Antibody

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease

Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients

Surface Confinement–induced Electrochemiluminescence Enhancement of Au Nanoclusters for Ultrasensitive Detection of a Soluble Urokinase-Type Plasminogen Activator Receptor

Relationship Between Plasma suPAR Level and Acute Coronary Syndrome With its Influencing Factors

Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis

Detection of phospholipase A2 in serum based on LRET mechanism between upconversion nanoparticles and SYBR green I

A Label-Free Photoelectrochemical Biosensor for Urokinase-Type Plasminogen Activator Detection Based on a G-C3n4/cds Nanocomposite

Clinical Significance of Measuring Soluble Urokinase-Type Plasminogen Activator Receptor in Cancerous Pleural Effusion

[Detection and Clinical Significance of Plasma Urokinase-Type Plasminogen Activator and Its Soluble Receptor in Patients with Multiple Myeloma].

An Anti-Urokinase Plasminogen Activator Receptor (upar) Antibody: Crystal Structure and Binding Epitope.

Expression and Identification of Recombinant Urokinase-Type Plasminogen Activator Receptor in Pichia Pastoris